Trials / Completed
CompletedNCT03289702
CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)
A Randomized, Double-blind, Active Drug Controlled, Multi-Center, Phase I/III Clinical Trial to Evaluate the Efficacy and Safety of CORETOX® in Treatment of Post Stroke Upper Limb Spasticity
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 220 (actual)
- Sponsor
- Medy-Tox · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of CORETOX® in the treatment of post-stroke upper limb spasticity
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CORETOX® | Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U. |
| DRUG | BOTOX® | Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U. |
Timeline
- Start date
- 2017-11-13
- Primary completion
- 2018-06-30
- Completion
- 2018-11-09
- First posted
- 2017-09-21
- Last updated
- 2021-12-07
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03289702. Inclusion in this directory is not an endorsement.